Comparative Pharmacology
Head-to-head clinical analysis: AYGESTIN versus DROSPIRENONE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AYGESTIN versus DROSPIRENONE.
AYGESTIN vs DROSPIRENONE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Progestin that suppresses gonadotropin secretion, inhibits ovulation, and induces endometrial changes by binding to progesterone receptors.
Spironolactone analog that antagonizes aldosterone at the mineralocorticoid receptor, leading to increased sodium and water excretion and potassium retention. Also has antiandrogenic activity by blocking androgen receptors and decreasing ovarian androgen production via inhibition of gonadotropin release.
5 mg orally once daily for secondary amenorrhea; 5 mg orally once daily from day 5 to day 25 of menstrual cycle for abnormal uterine bleeding.
3 mg orally once daily.
None Documented
None Documented
Terminal half-life 5-12 hours; clinical context: requires twice-daily dosing for consistent serum levels.
Clinical Note
moderateDrospirenone + Benzydamine
"Drospirenone may increase the hyperkalemic activities of Benzydamine."
Clinical Note
moderateDrospirenone + Droxicam
"Drospirenone may increase the hyperkalemic activities of Droxicam."
Clinical Note
moderateDrospirenone + Loxoprofen
"Drospirenone may increase the hyperkalemic activities of Loxoprofen."
Clinical Note
moderateDrospirenone + Clonixin
"Drospirenone may increase the hyperkalemic activities of Clonixin."
Terminal elimination half-life: ~30-35 hours (range 25-40 h); significant clinical accumulation occurs after repeated dosing, requiring 10-14 days to reach steady state.
Approximately 50-80% renal as metabolites, 10-20% fecal; less than 1% unchanged.
Renal: ~50% (as metabolites; <10% unchanged); Fecal: ~40-50% (as metabolites; bile-mediated); Urinary and fecal elimination account for >95% of an oral dose.
Category C
Category C
Progestin
Progestin